Quarterly report pursuant to Section 13 or 15(d)

Note 11 - Segment Information - Financial Information Relating to Reportable Segments (Details)

v3.8.0.1
Note 11 - Segment Information - Financial Information Relating to Reportable Segments (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Net sales $ 154,153 $ 131,807 $ 298,766 $ 262,388
Operating income 24,148 17,881 50,179 47,036
Amortization of acquisition related intangible assets     (22,675)  
Corporate general, selling, and administrative expenses (63,775) (56,981) (122,064) (102,405)
Acquisition Related [Member]        
Corporate general, selling, and administrative expenses (2,204) (710) (4,636) (2,293)
Operating Segments [Member]        
Operating income 56,106 47,118 109,594 96,110
Intersegment Eliminations [Member]        
Net sales (75) (24) (164) (36)
Segment Reconciling Items [Member]        
Costs recognized on sale of acquired inventory (264) (789) (582) (2,133)
Amortization of acquisition related intangible assets (11,296) (11,627) (22,675) (21,815)
Acquisition related expenses (13,150) (12,056) (22,683) (15,588)
Stock based compensation (5,044) (4,055) (8,839) (7,245)
Biotechnology [Member] | Operating Segments [Member]        
Net sales 101,411 85,953 196,487 172,740
Operating income 46,210 39,474 90,813 81,594
Protein Platforms [Member] | Operating Segments [Member]        
Net sales 29,388 21,548 54,028 41,121
Operating income 6,119 1,843 9,175 2,052
Diagnostics [Member] | Operating Segments [Member]        
Net sales 23,429 24,330 48,415 48,563
Operating income $ 3,777 $ 5,801 $ 9,606 $ 12,104